Identification of Novel Biomarker for Human Uterine Leiomyosarcoma
Journal Title: Journal of Hematology and Oncology Research - Year 2014, Vol 1, Issue 2
Abstract
Sarcomas are neoplastic malignancies that typically arise in tissues of mesenchymal origin. The identification of novel molecular mechanisms leading to sarcoma formation and the establishment of new therapies has been hampered by several critical factors. Human uterine leiomyosarcoma (Ut-LMS) develops more frequently in the muscle tissue layer of the uterine body than in the uterine cervix. Although the development of gynecologic tumors is often correlated with the secretion of female hormones; that of human Ut-LMS does not and its risk factors remain unknown. Importantly, a diagnostic biomarker that can distinguish malignant Ut-LMS from benign tumor uterine leiomyoma (LMA) has yet to be established. Therefore the risk factor(s) associated with human Ut-LMS to establish a diagnosis and novel therapeutic method. Proteasome b-ring subunit LMP2/b1i-deficient mice spontaneously develop Ut-LMS, with a disease prevalence of ~40% by 14 months of age. We shown that LMP2/b1i expression was absent in human Ut-LMS, but present in other human uterine mesenchymal tumors including uterine LMA. Therefore, defective-LMP2/b1i expression may be one of the risk factors for human Ut-LMS. LMP2/b1i is a potential diagnostic biomarker for human Ut-LMS, and may be a targeted-molecule for a new therapeutic approach.
Authors and Affiliations
Takuma Hayashi, Akiko Horiuchi, Hiroyuki Aburatani, Osamu Ishiko, Nobuo Yaegashi, Yae Kanai, Dorit Zharhary, Susumu Tonegawa, Ikuo Konishi
Keywords
Related Articles
- EP ID EP249387
- DOI 10.14302/issn.2372-6601.jhor-13-379
- Views 221
- Downloads 0
Drivers and Barriers to Medication Adherence in Patients with Chronic Myeloid Leukaemia: A Qualitative Study
With the introduction of tyrosine kinase inhibitors (TKI), patients with chronic myeloid leukemia (CML) have obtained survival rates close to normal. It may appear paradoxical, then, that medication adherence is suboptim...
Acute Onset Symptomatic Polycythaemia Vera
No Abstract
Erlotinib Associated Trichomegaly in a Patient with Chronic Latanoprost Use
Trichomegaly is a known adverse effect with the epidermal growth factor receptor inhibitor (EGFRI) and prostaglandin analogue drug classes. We present a chronic Latanoprost user who developed symptomatic trichomegaly sub...
Syndrome of Inappropriate Antidiuretic Hormone Secretion in a Patient with a Nodular Lymphocyte-Predominant Hodgkin Lymphoma. A Case Report and Review of Literature
Syndrome of inappropriate antidiuretic hormone secretion (SIADH) is a known side effect of several oncology drugs, but it is rarely seen secondary to vinblastine with only a few cases reported worldwide. Herein we presen...
Unusual Cutaneous Toxicity After Prolonged Use of Hydroxyurea in Polycythemia Vera: A Case Report
Hydroxyurea (HU) is commonly used for the long-term treatment of patients with chronic myeloproliferative neoplasms. The drug is usually well tolerated in the large majority of subjects, although systemic and/or localize...